These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 18400077)

  • 1. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
    Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
    Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
    Soriano V; Mocroft A; Peters L; Rockstroh J; Antunes F; Kirkby N; de Wit S; Monforte Ad; Flisiak R; Lundgren J;
    J Antimicrob Chemother; 2010 Mar; 65(3):548-55. PubMed ID: 20051475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic.
    Sheng WH; Chen MY; Hsieh SM; Hsiao CF; Wang JT; Hung CC; Chang SC
    Clin Infect Dis; 2004 May; 38(10):1471-7. PubMed ID: 15156487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
    Rouet F; Chaix ML; Inwoley A; Anaky MF; Fassinou P; Kpozehouen A; Rouzioux C; Blanche S; Msellati P;
    Clin Infect Dis; 2008 Feb; 46(3):361-6. PubMed ID: 18171303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
    Sagoe KW; Agyei AA; Ziga F; Lartey M; Adiku TK; Seshi M; Arens MQ; Mingle JA
    J Med Virol; 2012 Jan; 84(1):6-10. PubMed ID: 22095533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
    Bellini C; Keiser O; Chave JP; Evison J; Fehr J; Kaiser L; Weber R; Vernazza P; Bernasconi E; Telenti A; Cavassini M;
    HIV Med; 2009 Jan; 10(1):12-8. PubMed ID: 18795964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
    Petoumenos K; Ringland C;
    HIV Med; 2005 May; 6(3):155-63. PubMed ID: 15876281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.